top of page
Search

SaniMed Founder Jim Wu Attends JLABS “Build a Biotech” Forum to Explore the Path to Biotech Commercialization

On June 3, 2025, the Johnson & Johnson Innovation – JLABS hosted the high-profile “Build a Biotech” Forum at the Texas Medical Center Innovation Institute in Houston, bringing together startups, investors, industry experts, and technology transfer organizations. The forum centered around a critical industry theme: how to transform cutting-edge biotech ideas into sustainable commercial ventures.


ree

ree

Jim Wu, Founder of SaniMed Science Group and Chairman of BioTech (Shanghai) Technology Co., Ltd., was invited to attend the event. He joined global thought leaders in discussing the entrepreneurial journey of biotech innovation and the emerging trends in global technology translation.


ree

JJDC: One of the Oldest Corporate Venture Funds in the World

The strategic role of Johnson & Johnson Innovation – JJDC (Johnson & Johnson Development Corporation) stood out during the forum.


ree

Established in 1973, JJDC is one of the longest-standing corporate venture capital funds globally, with a focus on investing in early- to growth-stage life sciences companies across pharmaceuticals, biotechnology, medical devices, diagnostics, and digital health. More than just a capital provider, JJDC empowers its portfolio companies through Johnson & Johnson’s global network—accelerating their technology validation, clinical development, and market access.


With a mission centered on “science-first and patient-centric” innovation, JJDC collaborates closely with JLABS to build an end-to-end innovation ecosystem for startups, from early-stage development to commercial launch.



Strategic Impact: Investment Plus Enablement

What sets JJDC apart is its strategic integration with the Johnson & Johnson global ecosystem. Portfolio companies gain:

  • Access to Johnson & Johnson’s R&D networks for rapid technology and clinical validation;

  • Support for global clinical trial design and regulatory pathway consultation;

  • Guidance on product registration and market launch;

  • Channel access and expert networks across international healthcare markets.


ree

Numerous JJDC-backed companies have grown from startup to IPO or strategic acquisition, including:

  • Crinetics Pharmaceuticals (endocrine diseases),

  • Abiomed (cardiovascular devices, later acquired by Johnson & Johnson),

  • Verb Surgical (robotic surgery platform, a Google joint venture later integrated into Johnson & Johnson).


These cases demonstrate that JJDC is not just a financial investor, but a long-term strategic partner focused on synergistic industrial collaboration.



JLABS: An Innovation Accelerator Bridging Science and Business


ree

As a key platform under Johnson & Johnson Innovation, JLABS operates life sciences incubators across North America, Europe, and Asia, supporting startups in biopharma, medical devices, and digital health.


The Houston edition of the Build a Biotech forum is part of JLABS’s global mission to nurture early-stage companies. Through capital connections, strategic resources, and open access to scientific infrastructure, JLABS enables more startups to transition from lab bench to market launch.



Biotech Innovation: From Breakthrough to Real-World Impact

At the core of its mission, JLABS is committed to supporting early-stage biopharma companies across the entire innovation lifecycle—from R&D to commercialization.


ree

This year’s “Build a Biotech” forum directly addressed common challenges faced by startups, such as fundraising, IP protection, preclinical development, and regulatory navigation. With participation from JJDC executives, biotech entrepreneurs, and seasoned investors, the forum provided actionable insights and shared strategic perspectives to guide emerging companies toward successful translational outcomes.



SaniMed: Advancing Innovation Through Global Collaboration

As a technology-driven platform company focused on life sciences technology translation and cross-border investment, SaniMed Science Group actively participates in global innovation dialogues. Jim Wu’s participation in the JLABS forum exemplifies SaniMed’s ongoing commitment to global ecosystem engagement and strategic collaboration.


Looking ahead, SaniMed will continue to serve as a bridge and accelerator, helping more biotech innovations move from scientific discovery to clinical impact.

Yorumlar

bottom of page